The TypeSeqer assay workflow consists of a series of three PCR reactions, with a dilution or enzyme treatment between the steps, and is capable of individual detection of 52 HPV types, including all carcinogenic types. There are no individual sample purification or normalization steps required, allowing for a streamlined, high-throughput workflow with minimal hands-on time. The assay has been designed to operate on Thermo Fisher Scientific Ion next-generation sequencing (NGS) platforms as well as Illumina NGS instruments. Automated reports containing assay performance and detected HPV types per sample are provided to each requesting investigator.
Samples submitted to CGR for HPV genotyping will be run on the Ion NGS platforms. Previously extracted DNA is acceptable for submission. Submitted extracted DNA will be quantitatively assessed before final acceptance. For DNA extraction service associated with this assay, CGR requires 500 ul per sample in one of the following three sample media: STM, Surepath, or PreservCyt. A detailed manuscript for the assay is being prepared. Sufficient basic consultation with a subject matter expert is included with the service.